Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88 | Zendy

Richard Daifuku | Zendy; Kathy Haenftling | Zendy; Duncan Young | Zendy; Eric S. Groves | Zendy; Corinne Turrell | Zendy; Frederick J. Meyers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88

Author(s) -

Richard Daifuku,

Kathy Haenftling,

Duncan Young,

Eric S. Groves,

Corinne Turrell,

Frederick J. Meyers

Publication year - 1992

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.36.10.2349

Subject(s) - monoclonal antibody , antibody , monoclonal , immunology , virology , medicine , microbiology and biotechnology , chemistry , biology

Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research